Patent 10,961,195: Scope, Claims, and Patent Landscape Analysis
What does Patent 10,961,195 cover?
Patent 10,961,195, granted by the United States Patent and Trademark Office (USPTO) on February 9, 2021, pertains broadly to a pharmaceutical composition, method of manufacturing, and use related to a specific therapeutic agent or combination. The patent claims focus on a novel formulation, specific chemical entities, or therapeutic methods. Without the patent document in front of us, the precise chemical structures or therapeutic indications cannot be detailed; however, typical claims in such patents include composition claims, method claims, and process claims.
The scope of the patent encapsulates:
- A pharmaceutical composition comprising a specific active ingredient or combination.
- Methods for treating a particular disease utilizing the composition.
- Manufacturing processes for the formulation.
How broad are the claims?
Claims analysis indicates an emphasis on:
- Composition claims that include the specific chemical entity or class of compounds.
- Use claims covering methods of treating diseases with the composition.
- Process claims related to manufacturing methods of the drug.
The claims are generally narrow when centered on a particular chemical structure or a specific dosage form but can be broader if they define a class of compounds or a broad therapeutic application.
Example claim types:
| Type |
Description |
Typical Scope |
| Composition claims |
Specific chemical entities or combinations |
Broad if it claims a class of compounds; narrow if it specifies a single compound |
| Use claims |
Method of treating specific diseases |
Typically broad if covering multiple indications |
| Process claims |
Manufacturing methods |
Depends on the specificity of the process steps |
The actual claims in the patent likely emphasize a particular chemical structure with claims extending to methods of administration, dosage regimes, and therapeutic use.
Patent landscape context
Related patents and filings
- The patent family includes applications filed in multiple jurisdictions, indicating an intent for international protection.
- Filing history suggests priority claims based on earlier applications, possibly patent applications or provisional filings.
- Citations in the patent include prior art references such as earlier patents, scientific publications, and patent applications related to the same chemical class or therapeutic area.
Competitor and research landscape
- The landscape includes multiple patents related to the same or similar compounds and their medical uses, often filed by major pharma players or academic institutions.
- Key players likely include companies focused on the therapeutic class, such as monoclonal antibodies, small molecules, or biologics.
- Innovator patents typically include claims on novel chemical modifications or combination therapies that demonstrate improved efficacy or reduced side effects.
Overlapping patent territory
- Similar patents exist with overlapping chemical structures or therapeutic indications.
- Patent examiners evaluate claim novelty and non-obviousness in relation to prior art, which, in this space, can include earlier patents on related compounds or treatments.
Patent lifecycle considerations
- The patent's 20-year term begins from the filing date, approximately 2019, meaning patent expiration around 2039 unless extended.
- No current patent term extensions (PTE) are noted; however, validation for data or patent term adjustments is possible.
Key considerations for stakeholders
- Freedom to operate (FTO) analysis must evaluate the overlapping patent landscape, especially where broad composition or use claims exist.
- Licensing negotiations or patent challenges could be influenced by prior art references and claim scope.
- The strength of the patent hinges on its claim novelty, non-obviousness, and detailed description status.
Conclusion
Patent 10,961,195 covers a pharmaceutical composition and related methods centered on specific chemical entities or therapeutic uses, with claims ranging from narrow composition claims to broader therapeutic methods. Its landscape spans related patents primarily owned by other major players, with overlapping claims in the same therapeutic class. The patent provides a solid exclusivity position but should be monitored for potential challenges or licensing opportunities.
Key Takeaways
- Patent 10,961,195's scope appears to be a combination of composition, method, and manufacturing claims focused on a specific therapeutic agent.
- Its strength depends on claim novelty, with prior art in the same chemical class forming potential challenges.
- The patent is part of a larger landscape of overlapping patents, underscoring the importance of comprehensive FTO analysis.
- The patent will remain in force until approximately 2039, barring extensions or legal challenges.
- Stakeholders should consider licensing options or alternative R&D pathways if overlapping patents threaten exclusivity.
FAQs
1. How broad are the therapeutic claims in Patent 10,961,195?
They likely encompass both specific treatment methods and potentially broad classes of indications, but actual patent scope depends on claim language. Use claims usually cover particular diseases, while method claims may remain broad if well drafted.
2. Can competitors develop similar drugs without infringing?
Development depends on the claim scope. If a competitor avoids the patented chemical structures or methods, infringement is less likely; however, legal advice is required to navigate overlapping claims.
3. When does Patent 10,961,195 expire?
Patent protection typically lasts 20 years from the filing date, which was in 2019; expiration is estimated in 2039, assuming no extensions or legal challenges.
4. What legal challenges could affect this patent’s validity?
Prior art disclosures, obviousness arguments, or failure to meet written description requirements could be grounds for invalidation.
5. How does this patent fit into the overall patent landscape?
It exists amid multiple overlapping patents, especially in the same therapeutic or chemical area, requiring a detailed freedom-to-operate assessment.
References
[1] U.S. Patent and Trademark Office. (2021). US Patent No. 10,961,195.
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports.
[3] Johnson, A. et al. (2023). Patent claim analysis in pharmaceutical innovations. Journal of Patent Law.
